TY - JOUR T1 - Interventions to address polypharmacy in older adults living with multimorbidity JF - Canadian Family Physician JO - Can Fam Physician SP - e215 LP - e226 DO - 10.46747/cfp.6807e215 VL - 68 IS - 7 AU - Muhammad Usman Ali AU - Diana Sherifali AU - Donna Fitzpatrick-Lewis AU - Meghan Kenny AU - Larkin Lamarche AU - Parminder Raina AU - Derelie Mangin Y1 - 2022/07/01 UR - http://www.cfp.ca/content/68/7/e215.abstract N2 - Objective To summarize evidence from published systematic reviews evaluating the effect of polypharmacy interventions on clinical and intermediate outcomes. It also summarizes the adverse events that may occur as a result of these interventions.Data sources A literature search was conducted using the electronic databases MEDLINE, Embase, CINAHL, Cochrane Central, and Cochrane Database of Systematic Reviews (PROSPERO registration number: CRD42018085767).Study selection The search yielded a total of 21,329 citations, of which 619 were reviewed as full text and 5 met the selection criteria.Synthesis The polypharmacy interventions were found to produce statistically significant reductions in potentially inappropriate prescribing and improved medication adherence; however, the observed effects on clinical and intermediate outcomes were inconsistent. None of the included reviews reported any significant benefit of polypharmacy interventions for quality-of-life outcomes. Specific to health care utilization and cost, polypharmacy interventions reduced health care resource usage and expenditure. The reviews reported no differences in adverse drug events between polypharmacy interventions and usual care groups. The overall certainty of evidence was reported as low to very low across included reviews.Conclusion Polypharmacy interventions are associated with reductions in potentially inappropriate prescribing and improvements in medication adherence. However, there is limited evidence of their effectiveness for clinical and intermediate outcomes. ER -